Comparing different dosing regimens of bevacizumab in the treatment of neovascular macular degeneration: study protocol for a randomised controlled trial

BACKGROUND: Bevacizumab (Avastin®) is as effective as ranibizumab (Lucentis®) in the treatment of neovascular age-related macular degeneration (nAMD). However it has two important structural differences. First, it has two active sites instead of one; second, it retains the Fc portion of the antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Foss, Alexander JE, Childs, Margaret, Reeves, Barnaby C, Empeslidis, Theo, Tesha, Paul, Dhar-Munshi, Sushma, Mughal, Samah, Culliford, Lucy, Rogers, Chris A, Tan, Wei, Montgomery, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376508/
https://www.ncbi.nlm.nih.gov/pubmed/25873213
http://dx.doi.org/10.1186/s13063-015-0608-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376508/
https://www.ncbi.nlm.nih.gov/pubmed/25873213
http://dx.doi.org/10.1186/s13063-015-0608-2

Ejemplares similares